[1] |
ZHOU MG, WANG HD, ZENG XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394( 10204): 1145- 1158. DOI: 10.1016/S0140-6736(19)30427-1.
|
[2] |
CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66( 2): 115- 132. DOI: 10.3322/caac.21338.
|
[3] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
|
[4] |
ZOU YW, REN ZG, SUN Y, et al. The latest research progress on minimally invasive treatments for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2023, 22( 1): 54- 63. DOI: 10.1016/j.hbpd.2022.08.004.
|
[5] |
QIAN K, ZHANG F, ALLISON SK, et al. Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status[J]. J Interv Med, 2021, 4( 1): 1- 7. DOI: 10.1016/j.jimed.2020.10.008.
|
[6] |
CHEN MS, LI JQ, ZHENG Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243( 3): 321- 328. DOI: 10.1097/01.sla.0000201480.65519.b8.
|
[7] |
FENG K, YAN J, LI XW, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012, 57( 4): 794- 802. DOI: 10.1016/j.jhep.2012.05.007.
|
[8] |
Bureau of Medical Administration, National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36( 2): 277- 292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36( 2): 277- 292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[9] |
EL-AGAWY W, EL-GANAINY SA, GAD MAA, et al. Combined transarterial chemoembolization with microwave ablation versus microwave alone for treatment of medium sized hepatocellular carcinoma[J]. Curr Cancer Drug Targets, 2022, 22( 1): 77- 85. DOI: 10.2174/1568009622666220117094146.
|
[10] |
ZHU SD, ZHENG L. Advances in clinical application of percutaneous thermal ablation for hepatocellular carcinoma[J]. J Interv Radiol, 2022, 31( 12): 1224- 1227. DOI: 10.3969/j.issn.1008-794X.2022.12.020.朱诗迪, 郑琳. 经皮穿刺热消融术在肝细胞癌中的临床应用进展[J]. 介入放射学杂志, 2022, 31( 12): 1224- 1227. DOI: 10.3969/j.issn.1008-794X.2022.12.020.
|
[11] |
LIU J, ZHOU Y, YU T, et al. Minimally invasive probe system capable of performing both cryosurgery and hyperthermia treatment on target tumor in deep tissues[J]. Minim Invasive Ther Allied Technol, 2004, 13( 1): 47- 57. DOI: 10.1080/13645700310022691.
|
[12] |
CHU KF, DUPUY DE. Thermal ablation of tumours: Biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14( 3): 199- 208. DOI: 10.1038/nrc3672.
|
[13] |
YAN JF, DENG ZS, LIU J, et al. New modality for maximizing cryosurgical killing scope while minimizing mechanical incision trauma using combined freezing-heating system[J]. J Med Devices, 2007, 1( 4): 264- 271. DOI: 10.1115/1.2812423.
|
[14] |
CHEN ZN, MENG LL, ZHANG J, et al. Progress in the cryoablation and cryoimmunotherapy for tumor[J]. Front Immunol, 2023, 14: 1094009. DOI: 10.3389/fimmu.2023.1094009.
|
[15] |
ZHU J, ZHANG Y, ZHANG AL, et al. Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation[J]. Sci Rep, 2016, 6: 27136. DOI: 10.1038/srep27136.
|
[16] |
SHEN YY, LIU P, ZHANG AL, et al. Tumor microvasculature response to alternated cold and heat treatment[J]. Conf Proc IEEE Eng Med Biol Soc, 2005, 2005: 6797- 6800. DOI: 10.1109/IEMBS.2005.1616065.
|
[17] |
DONG JX, LIU P, ZHANG AL, et al. Immunological response induced by alternated cooling and heating of breast tumor[J]. Conf Proc IEEE Eng Med Biol Soc, 2007, 2007: 1491- 1494. DOI: 10.1109/IEMBS.2007.4352583.
|
[18] |
LIU K, HE K, XUE T, et al. The cryo-thermal therapy-induced IL-6-rich acute pro-inflammatory response promoted DCs phenotypic maturation as the prerequisite to CD4+ T cell differentiation[J]. Int J Hyperthermia, 2018, 34( 3): 261- 272. DOI: 10.1080/02656736.2017.1332394.
|
[19] |
Committee of Minimally Invasive Therapy in Oncology, Chinese AntiCancer Association. Chinese College of Interventionalists;Expert Committee on Interventional Therapy, Chinese Society of Clinical Oncolog(CSCO), et al. Expert consensus on clinical practice of multi-model ablation for treatment of liver malignant tumors[J]. Chin J Interv Imag Ther, 2021, 18( 1): 23- 27. DOI: 10.13929/j.issn.1672-8475.2021.01.006.中国抗癌协会肿瘤介入学专业委员会, 中国医师协会介入医师分会, 中国临床肿瘤学会(CSCO)放射介入治疗专家委员会, 等. 冷热多模态消融治疗肝脏恶性肿瘤操作规范专家共识[J]. 中国介入影像与治疗学, 2021, 18( 1): 23- 27. DOI: 10.13929/j.issn.1672-8475.2021.01.006.
|
[20] |
Committee of Minimally Invasive Therapy in Oncology, Chinese AntiCancer Association. Chinese College of Interventionalists; Expert Committee on Interventional Therapy, Chinese Society of Clinical Oncolog(CSCO), et al. Expert consensus on clinical practice of percutaneous multi-modal cold and hot ablation for treatment of pulmonary malignant tumor[J]. Chin J Interv Imag Ther, 2020, 17: 705- 710. DOI: 10.13929/j.issn.1672-8475.2021.01.006.中国抗癌协会肿瘤介入学专业委员会, 中国医师协会介入医师分会, 中国临床肿瘤学会(CSCO)放射介入治疗专家委员会, 等. 经皮穿刺冷热多模态消融治疗肺部恶性肿瘤操作规范专家共识[J]. 中国介入影像与治疗学, 2020, 17: 705- 710. DOI: 10.13929/j.issn.1672-8475.2021.01.006.
|
[21] |
The Society of Interventional Therapy, China Anticancer Association, The Solid Tumor Theranostics Committee, Shanghai Anticancer Association. Expert consensus on the imaging-guided multimode tumor ablation therapy system for malignant hepatic tumors[J]. J Interv Radiol, 2018, 27( 7): 603- 607. DOI: 10.3969/j.issn.1008-794X.2018.07.001.中国抗癌协会肿瘤介入学专业委员会, 上海市抗癌协会实体肿瘤聚焦诊疗专业委员会. 影像导引肝脏恶性肿瘤多模态消融治疗技术专家共识[J]. 介入放射学杂志, 2018, 27( 7): 603- 607. DOI: 10.3969/j.issn.1008-794X.2018.07.001.
|
[22] |
YANG WW, AN YH, LI QW, et al. Co-ablation versus cryoablation for the treatment of stage Ⅲ-Ⅳ non-small cell lung cancer: A prospective, noninferiority, randomized, controlled trial(RCT)[J]. Thorac Cancer, 2021, 12( 4): 475- 483. DOI: 10.1111/1759-7714.13779.
|